Posted by Michael Wonder on 26 Jun 2019
Pacira BioSciences announces validation of Exparel marketing authorisation application from European Medicines Agency
25 June 2019 - Advances global expansion strategy to minimise post-surgical opioid use worldwide.
Pacira BioSciences today announced that the company’s marketing authorisation application for Exparel (bupivacaine liposome injectable suspension) for post-surgical analgesia was validated by the EMA.
With this validation, the Pacira application is complete and the EMA CHMP will now begin the review procedure with an opinion expected in the second half of 2020.
